AIRNA, a biotechnology company headquartered in Cambridge, announced $155 million in an oversubscribed Series B funding round from lead investors Venrock Healthcare Capital Partners and Forbion Growth. The company leverages RNA editing therapeutics to help improve the lives of patients with rare and common diseases.
The new funding allows AIRNA to advance its lead candidate into the next phase of clinical trials. This product, AIR-001, is made to treat Alpha-1 antitrypsin deficiency, or AATD, a genetic condition that may lead to lung and liver disease. AIRNA also plans to develop a pipeline of medicines for cardiometabolic and other diseases.
“AIRNA is developing a new class of genetic medicines that could provide functional cures for a wide range of diseases,” Kris Elverum, AIRNA’s president and CEO, said in a statement. “This partnership of new and existing investors allows us to rapidly deliver AIR-001 to patients with AATD, as well as progress a pipeline of medicines to realize the full potential of RNA editing.”
